ContractAsset Purchase Agreement • November 25th, 2015 • Viventia Bio Inc. • Biological products, (no disgnostic substances) • Ontario
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
ContractLicense Agreement • November 25th, 2015 • Viventia Bio Inc. • Biological products, (no disgnostic substances)
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
AMENDED & RESTATED EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 25th, 2015 • Viventia Bio Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive License Agreement (this “Agreement”) is effective as of the 8th day of March, 2004,(the “Effective Date”) and amended and restated as of October 14, 2015 to reflect Amendment 1 and 2 between Merck KGaA, of Frankfurter Str. 250, 64293 Darmstadt, Germany (hereinafter called “Merck,” which expression includes its successors and assigns) of the one part and Viventia Bio, Inc., of 147 Hamelin Street, Winnipeg MB, R3T 3Z1, CANADA (hereinafter called “Viventia,” which expression includes its successors and permitted assignees) of the other part. Each of Merck and Viventia are herein sometimes referred to individually as a “Party” and collectively as “Parties.”
